The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

Recent health news highlights key regulatory approvals and legal actions. The EU backs Novo Nordisk's Wegovy for an ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...

*Based on data released by the Federal Election Commission on September 18, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands ...

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary ...